ClinicalTrials.gg
CompletedNCT01562314Updated Aug 9, 2018Results posted

A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)

A Phase 2 interventional study of GWP42003 and Placebo in Ulcerative Colitis, sponsored by GW Research Ltd. Completed at 8 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by GW Research Ltd (part of Jazz Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 215 studies in Colitis, Ulcerative with a site in United Kingdom — 29 open to participants now, 60 under way, 25 of them phase 3. Colitis, Ulcerative · United Kingdom.

Enrollment
135th of 178
60 · median 143
Started
2012
with 8 others
Phase 2
57 of 215
4 open now
Registered
36th of 215
by date

Among the 215 studies in Colitis, Ulcerative with a site in United Kingdom, this one is the 135th largest by enrollment of the 178 interventional ones that give a count, is one of 9 that started in 2012, is one of 57 in phase 2, and was the 36th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

29 of the 215 studies in Colitis, Ulcerative with a site in United Kingdom are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Colitis, Ulcerative with a site in United Kingdom, or all of them as a file.
02

Study summary

This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks of treatment.

Read the detailed description

This study was conducted by GW Research Ltd as a pilot study to determine the efficacy and safety of GWP42003 (50 milligram [mg] up to 250 mg twice daily [BID]), compared with placebo, as assessed by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks of treatment. This was the first study to determine whether the study drug has a positive benefit for participants on their ulcerative colitis symptom control, as well as effects on inflammatory marker cytokines (C reactive protein [CRP]), a fecal inflammatory marker (calprotectin), stool frequency, and rectal bleeding. In addition, various inflammatory bowel disease (IBD) questionnaires were implemented in the study to observe further benefits on the study drug, compared with placebo.

This study was multi-center, randomized, double-blind, placebo-controlled, and parallel-group. The study consisted of a 7-day baseline period, a 10-week treatment period, and a 1-week follow-up period. Each participant had a Mayo assessment (including endoscopy) conducted to confirm eligibility. Eligible participants were randomized in a 1:1 ratio into the GWP42003 and placebo groups. At the start of the treatment period, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 250 mg BID in the GWP42003 group. Participants remained at the maximum tolerated dose for the rest of the treatment period.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Mild to Moderate Ulcerative Colitis
  • GWP42003
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 years or above;
  • Participant diagnosed with mild to moderate ulcerative colitis and on a fixed dose of 5-Aminosalicylic (5-ASA) treatment and have been on a stable dose for at least 2 weeks prior to screening (0 mg dose of 5-ASA was acceptable);
  • Participants at screening and baseline with a Mayo assessment score of greater than or equal to 4 (≥4) but less than or equal to 10 (≤10) and with an endoscopy score of at least 1 (≥1) , following an adequate exposure to oral and/ or topical 5-ASA, in the opinion of the investigator;
  • In the opinion of the investigator, capable of complying with the study requirements and completing the study;
  • Willing and able to give ;
  • Willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable;
  • Willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study;

Exclusion criteria

Exclusion Criteria:

  • Severe ulcerative colitis (Mayo score of greater than 10 (>10);
  • Ulcerative colitis only affecting the rectum (proctitis)
  • Gastrointestinal infection evident from stool culture and testing for Clostridium difficile toxin (in the opinion of the investigator);
  • Currently using or had used recreational cannabis, medicinal cannabis, cannabinoid medications (including Sativex®), or synthetic cannabinoid-based medications within 1 month prior to study entry and unwilling to abstain for the duration of the study;
  • Any known or suspected history of alcohol or substance abuse, epilepsy or recurrent seizures, or to cannabinoids;
  • Was receiving a prohibited medication prior to screening and for the duration of the study;
  • Previous non-responders to mono or polyclonal anti-Tumor Necrosis Factor antibodies;
  • Personal or first degree relative, with history of schizophrenia or other psychosis;
  • History of other significant psychiatric disorder or severe personality disorder (at the discretion of the investigator);
  • Any known or suspected history of depression sufficient to require treatment with antidepressants or disrupt ordinary life (excluding episodes of reactive depression at the discretion of the investigator);
  • cardiac, renal or hepatic impairment in the opinion of the investigator;
  • Female participants who were pregnant, lactating or planning pregnancy during the course of the study and for 3 months from the date of last dose;
  • Female participants of child bearing potential, unless willing to use 2 forms of , 1 of which must have been a barrier contraception (for example, a female condom or occlusive cap [diaphragm or cervical vault/caps] with spermicide) during the study and for 3 months from the date of last dose (however a male condom should not have been used in conjunction with the female condom);
  • Male participants whose partner was of child bearing potential, unless willing to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (for example, an occlusive cap [diaphragm or cervical vault/caps] with spermicide) during the study and for 3 months from date of last dose (however a male condom should not have been used in conjunction with a female condom);
  • Planned to travel outside the country of residence during the treatment phase of the study;
  • Received an Medicinal Product (IMP) within 30 days prior to the screening visit;
  • In the opinion of the investigator, was not considered to be suitable for the study;
  • Any other significant disease or disorder which, in the opinion of the investigator, may either have put the participant at risk because of participation in the study, or may have influenced the result of the study or the participant's ability to participate in the study;
  • Participant with any abnormalities that, in the opinion of the investigator, would prevent the participant from safe participation in the study;
  • Unwilling to abstain from donation of blood during the study;
  • Participants previously randomized into this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    GWP42003

    GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.

    Drug: GWP42003

  • Placebo comparator
    Placebo

    Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.

    Drug: Placebo

Interventions

  • 1 to 5 50 mg capsules taken BID

    Also known as: Cannabidiol (CBD) Botanical Drug Substance (BDS)

  • DrugPlacebo

    1 to 5 matching capsules taken BID

    Also known as: Placebo control

06

What researchers measure

Primary outcomes

  1. Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT

    The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); Physician's Global Assessment of Illness Severity (PGAS): 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

    Time frame: Baseline to End of Treatment (EOT) (10 weeks) or Early Termination (ET)

  2. Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis

    The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

    Time frame: Baseline to EOT (10 weeks) or ET

Secondary outcomes

  1. Distribution On The PGAS At EOT

    The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).

    Time frame: EOT (10 weeks) or ET

  2. Distribution On The PGAS At EOT - PP Analysis

    The PGAS required the physician to assess participants' disease severity on a 4-point scale (0 = normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).

    Time frame: EOT (10 weeks) or ET

  3. Change From Baseline To EOT In The PGAS Score

    The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.

    Time frame: Baseline to EOT (10 weeks) or ET

  4. Change From Baseline To EOT In The PGAS Score - PP Analysis

    The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.

    Time frame: Baseline to EOT (10 weeks) or ET

  5. Change From Baseline To EOT In The Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with inflammatory bowel disease (IBD). Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (10 weeks) or ET

  6. Change From Baseline To EOT In The IBDQ Total Score - PP Analysis

    The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with IBD. Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (10 weeks) or ET

  7. Number Of Participants Who Reported An Improvement In The Subject Global Impression Of Change (SGIC) Questionnaire At EOT

    Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.

    Time frame: Visit 4 (Day 43) to EOT (10 weeks) or ET

  8. Number Of Participants Who Reported An Improvement In The SGIC Questionnaire At EOT - PP Analysis

    Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.

    Time frame: Visit 4 (Day 43) to EOT (10 weeks) or ET

  9. Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency Numerical Rating Scale (NRS)

    Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (last 7 days) or ET

  10. Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency NRS - PP Analysis

    Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (last 7 days) or ET

  11. Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS

    Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (last 7 days) or ET

  12. Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS - PP Analysis

    Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (last 7 days) or ET

  13. Change From Baseline To EOT In The Mayo Total Score

    The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores (assessed using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (10 weeks) or ET

  14. Change From Baseline To EOT In The Mayo Partial Score

    The Mayo score is an assessment of ulcerative colitis activity. The Mayo partial score does not include the endoscopy findings sub-score and ranges from 0 to 9 points with higher scores indicating more severe disease. The partial score is made up of 3 sub-scores (assessed by using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.

    Time frame: Baseline to EOT (10 weeks) or ET

  15. Change From Baseline To EOT In Levels Of Fecal Calprotectin

    Fecal calprotectin is a marker of inflammation. Standard methods were used to measure the levels of calprotectin in fecal samples collected at the end of baseline and treatment periods. A negative change from Baseline indicates that levels of fecal calprotectin decreased.

    Time frame: Baseline to EOT (10 weeks) or ET

07

Results

Posted Aug 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneGWP42003Placebo
Started2931
Received at least 1 dose of study drug2931
Intent-to-treat (itt) analysis set2931
Per protocol (pp) analysis set1727
Completed1623
Not completed138
Withdrew: Adverse event105
Withdrew: Met withdrawal criteria32
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT

The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); Physician's Global Assessment of Illness Severity (PGAS): 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

Time frame:
Baseline to End of Treatment (EOT) (10 weeks) or Early Termination (ET)
Reported as:
Count of participants · Participants
Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT
ParticipantsGWP42003Placebo
Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT88
Statistical analysis
  • GWP42003 vs Placebo · Regression, Logistic · p = 0.7532 · Odds ratio (or): 0.821 · 90% CI 0.292 to 2.309
PrimaryNumber Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis

The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Count of participants · Participants
Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis
ParticipantsGWP42003Placebo
Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis78
Statistical analysis
  • GWP42003 vs Placebo · Regression, Logistic · p = 0.7032 · Odds ratio (or): 1.300 · 90% CI 0.419 to 4.040
SecondaryDistribution On The PGAS At EOT

The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).

Time frame:
EOT (10 weeks) or ET
Reported as:
Count of participants · Participants
Distribution On The PGAS At EOT
ParticipantsGWP42003Placebo
Normal75
Mild Disease1311
Moderate Disease612
Severe Disease03
SecondaryDistribution On The PGAS At EOT - PP Analysis

The PGAS required the physician to assess participants' disease severity on a 4-point scale (0 = normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).

Time frame:
EOT (10 weeks) or ET
Reported as:
Count of participants · Participants
Distribution On The PGAS At EOT - PP Analysis
ParticipantsGWP42003Placebo
Normal65
Mild Disease89
Moderate Disease311
Severe Disease02
SecondaryChange From Baseline To EOT In The PGAS Score

The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The PGAS Score
units on a scaleGWP42003Placebo
Baseline1.7 ± 0.451.8 ± 0.48
Final Visit1.0 ± 0.721.4 ± 0.89
Change From Baseline-0.8 ± 0.82-0.4 ± 0.95
SecondaryChange From Baseline To EOT In The PGAS Score - PP Analysis

The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The PGAS Score - PP Analysis
units on a scaleGWP42003Placebo
Baseline1.8 ± 0.441.8 ± 0.51
Final Visit0.8 ± 0.731.4 ± 0.88
Change From Baseline-0.9 ± 0.83-0.4 ± 0.97
SecondaryChange From Baseline To EOT In The Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with inflammatory bowel disease (IBD). Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
units on a scaleGWP42003Placebo
Baseline138.5 ± 32.37129.1 ± 38.02
Final Visit164.2 ± 29.13146.8 ± 47.50
Change From Baseline24.6 ± 35.5116.7 ± 36.33
SecondaryChange From Baseline To EOT In The IBDQ Total Score - PP Analysis

The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with IBD. Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The IBDQ Total Score - PP Analysis
units on a scaleGWP42003Placebo
Baseline134.0 ± 35.58134.0 ± 37.30
Final Visit172.8 ± 28.52150.5 ± 48.87
Change From Baseline39.3 ± 39.8115.4 ± 33.65
SecondaryNumber Of Participants Who Reported An Improvement In The Subject Global Impression Of Change (SGIC) Questionnaire At EOT

Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.

Time frame:
Visit 4 (Day 43) to EOT (10 weeks) or ET
Reported as:
Count of participants · Participants
Number Of Participants Who Reported An Improvement In The Subject Global Impression Of Change (SGIC) Questionnaire At EOT
ParticipantsGWP42003Placebo
Visit 4 (Day 43)1518
Final Visit2317
SecondaryNumber Of Participants Who Reported An Improvement In The SGIC Questionnaire At EOT - PP Analysis

Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.

Time frame:
Visit 4 (Day 43) to EOT (10 weeks) or ET
Reported as:
Count of participants · Participants
Number Of Participants Who Reported An Improvement In The SGIC Questionnaire At EOT - PP Analysis
ParticipantsGWP42003Placebo
Visit 4 (Day 43)1418
Final Visit1616
SecondaryChange From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency Numerical Rating Scale (NRS)

Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (last 7 days) or ET
Reported as:
Mean · units on a scale
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency Numerical Rating Scale (NRS)
units on a scaleGWP42003Placebo
Baseline1.50 ± 0.9371.89 ± 0.814
Last 7 Days1.05 ± 0.9301.46 ± 0.888
Change From Baseline-0.43 ± 0.563-0.43 ± 0.816
SecondaryChange From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency NRS - PP Analysis

Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (last 7 days) or ET
Reported as:
Mean · units on a scale
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency NRS - PP Analysis
units on a scaleGWP42003Placebo
Baseline1.37 ± 0.8751.81 ± 0.827
Last 7 Days0.73 ± 0.6891.36 ± 0.871
Change From Baseline-0.64 ± 0.497-0.45 ± 0.768
SecondaryChange From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS

Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (last 7 days) or ET
Reported as:
Mean · units on a scale
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS
units on a scaleGWP42003Placebo
Baseline0.96 ± 0.8291.19 ± 0.816
Last 7 Days0.48 ± 0.7110.84 ± 0.863
Change From Baseline-0.44 ± 0.709-0.35 ± 0.794
SecondaryChange From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS - PP Analysis

Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (last 7 days) or ET
Reported as:
Mean · units on a scale
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS - PP Analysis
units on a scaleGWP42003Placebo
Baseline0.82 ± 0.6821.16 ± 0.831
Last 7 Days0.24 ± 0.3670.80 ± 0.875
Change From Baseline-0.58 ± 0.793-0.35 ± 0.773
SecondaryChange From Baseline To EOT In The Mayo Total Score

The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores (assessed using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The Mayo Total Score
units on a scaleGWP42003Placebo
Baseline6.3 ± 1.737.0 ± 2.01
Final Visit3.0 ± 2.254.9 ± 3.22
Change From Baseline-3.0 ± 2.40-1.8 ± 2.73
SecondaryChange From Baseline To EOT In The Mayo Partial Score

The Mayo score is an assessment of ulcerative colitis activity. The Mayo partial score does not include the endoscopy findings sub-score and ranges from 0 to 9 points with higher scores indicating more severe disease. The partial score is made up of 3 sub-scores (assessed by using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The Mayo Partial Score
units on a scaleGWP42003Placebo
Baseline4.4 ± 1.575.1 ± 1.61
Final Visit2.3 ± 1.733.8 ± 2.60
Change From Baseline-2.0 ± 2.00-1.2 ± 2.14
SecondaryChange From Baseline To EOT In Levels Of Fecal Calprotectin

Fecal calprotectin is a marker of inflammation. Standard methods were used to measure the levels of calprotectin in fecal samples collected at the end of baseline and treatment periods. A negative change from Baseline indicates that levels of fecal calprotectin decreased.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · microgram calprotectin/gram feces (ug/g)
Change From Baseline To EOT In Levels Of Fecal Calprotectin
microgram calprotectin/gram feces (ug/g)GWP42003Placebo
Baseline490.6 ± 197.41462.3 ± 227.35
Final Visit397.3 ± 241.08428.0 ± 229.38
Change from Baseline-91.6 ± 295.77-51.3 ± 289.32
Post-hocChange From Baseline To EOT In The Mayo Total Score - PP Analysis

The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores (assessed using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The Mayo Total Score - PP Analysis
units on a scaleGWP42003Placebo
Baseline6.0 ± 1.706.8 ± 2.04
Final Visit2.8 ± 2.024.7 ± 3.24
Change From Baseline-3.2 ± 2.25-1.9 ± 2.81
Post-hocChange From Baseline To EOT In The Mayo Partial Score - PP Analysis Set

The Mayo score is an assessment of ulcerative colitis activity. The Mayo partial score does not include the endoscopy findings sub-score and ranges from 0 to 9 points with higher scores indicating more severe disease. The partial score is made up of 3 sub-scores (assessed by using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. A negative change from Baseline indicates that symptoms improved.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · units on a scale
Change From Baseline To EOT In The Mayo Partial Score - PP Analysis Set
units on a scaleGWP42003Placebo
Baseline4.1 ± 1.504.9 ± 1.63
Final Visit1.7 ± 1.533.7 ± 2.66
Change From Baseline-2.4 ± 2.03-1.2 ± 2.17
Post-hocChange From Baseline To EOT In Levels Of Fecal Calprotectin- PP Analysis

Fecal calprotectin is a marker of inflammation. Standard methods were used to measure the levels of calprotectin in fecal samples collected at the end of baseline and treatment periods. A negative change from Baseline indicates that levels of fecal calprotectin decreased.

Time frame:
Baseline to EOT (10 weeks) or ET
Reported as:
Mean · ug/g
Change From Baseline To EOT In Levels Of Fecal Calprotectin- PP Analysis
ug/gGWP42003Placebo
Baseline527.9 ± 164.14440.3 ± 237.99
Final Visit355.9 ± 247.75408.9 ± 238.94
Change From Baseline-155.9 ± 306.84-51.9 ± 311.56

Adverse events

Collected over Post-dose on Day 1 through 14 days after the final dose (up to 85 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003—0/29 (0%)28/29 (96.6%)
Placebo—4/31 (12.9%)23/31 (74.2%)
Most frequent serious events
Most frequent serious events
EventGWP42003Placebo
PregnancyPregnancy, puerperium and perinatal conditions0/61/10
Colitis ulcerativeGastrointestinal disorders0/292/31
Chest painGeneral disorders0/291/31
Most frequent other events
Showing 10 of 24
Most frequent other events
EventGWP42003Placebo
DizzinessNervous system disorders12/293/31
SomnolenceNervous system disorders10/292/31
NauseaGastrointestinal disorders8/293/31
Disturbance in attentionNervous system disorders5/290/31
Abdominal painGastrointestinal disorders1/295/31
Dry mouthGastrointestinal disorders4/290/31
VomitingGastrointestinal disorders4/290/31
FatigueGeneral disorders4/294/31
HeadacheNervous system disorders4/294/31
DisorientationPsychiatric disorders4/290/31

Baseline characteristics

Intent-to-treat (ITT) analysis set: all participants who were randomized and received at least 1 dose of study drug. Participants were analyzed according to the group to which they were randomized.

Age, Continuous
Age, Continuous(years)GWP42003PlaceboTotal
Mean44.78 ± 15.05042.82 ± 12.91643.77 ± 13.903
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003PlaceboTotal
Female61016
Male232144
08

Study locations

8 sites
  • Birmingham, B15 2TH, United Kingdom
  • Coventry, CV2 2DX, United Kingdom
  • Liverpool, L7 8XP, United Kingdom
  • London, NW1 2PG, United Kingdom
  • London, NW3 2QG, United Kingdom
  • London, SE1 7EH, United Kingdom
  • Middlesex, HA1 3UJ, United Kingdom
  • Wigan, WN1 2NN, United Kingdom
09

References and documents

Publications

  • Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018 Mar 19;24(4):714-724. doi: 10.1093/ibd/izy002. PubMed 29538683 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Aug 2014, 26 months.

Results were first posted in Aug 2015, 1 year after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 26 months is close to that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
StartActual
May 9, 2012
Primary completionActual
Aug 5, 2014
CompletionActual
Aug 5, 2014
Results first posted
Aug 14, 2015
Last update
Aug 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01562314
Lead sponsor
GW Research Ltd
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
May 9, 2012
Primary completion
Aug 5, 2014
Completion
Aug 5, 2014
Results posted
Aug 14, 2015
Last update
Aug 9, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion